Pulse corticosteroid therapy for alopecia areata: study of 139 patients

Dermatology. 2007;215(4):320-4. doi: 10.1159/000107626.

Abstract

Background/aim: Recent reports of pulse corticosteroid therapy for alopecia areata (AA) show its efficacy for patients with a history of < or = 1 year but not for recalcitrant cases or alopecia totalis/universalis. The purpose of this study was to evaluate the efficacy and safety of pulse corticosteroid therapy for recent-onset AA patients.

Method: A total of 139 severe AA patients aged >15 years were included in this study. The duration from the onset of active hair loss was within 12 months for 125 (89.9%) of those patients.

Results: Of the patients, 72.7% had hair loss on > 50% of their scalp area. Among the recent-onset group (duration of AA < or = 6 months), 59.4% were good responders (> 75% regrowth of alopecia lesions), while 15.8% with > 6 months duration showed a good response. Recent-onset AA patients with less severe disease (< or = 50% hair loss) responded at a rate of 88.0%, but only 21.4% of recent-onset patients with 100% hair loss responded. No serious adverse effects were observed.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Alopecia Areata / drug therapy*
  • Alopecia Areata / pathology
  • Biopsy
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Glucocorticoids / administration & dosage*
  • Hair / growth & development
  • Humans
  • Injections, Intravenous
  • Male
  • Methylprednisolone / administration & dosage*
  • Middle Aged
  • Pulse Therapy, Drug
  • Retrospective Studies
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Methylprednisolone